INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 346 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41 | +78.3% | 1,900 | +35.7% | 0.00% | +33.3% |
| Q2 2023 | $23 | +15.0% | 1,400 | +133.3% | 0.00% | +50.0% |
| Q1 2023 | $20 | -13.0% | 600 | -40.0% | 0.00% | 0.0% |
| Q4 2022 | $23 | -100.0% | 1,000 | -94.4% | 0.00% | -95.1% |
| Q3 2022 | $590,000 | +15.9% | 18,000 | +50.0% | 0.04% | +17.1% |
| Q2 2022 | $509,000 | -2.5% | 12,000 | +0.9% | 0.04% | +29.6% |
| Q1 2022 | $522,000 | +1907.7% | 11,894 | +2873.5% | 0.03% | +2600.0% |
| Q4 2021 | $26,000 | -51.9% | 400 | -74.0% | 0.00% | -50.0% |
| Q3 2021 | $54,000 | -97.0% | 1,540 | -95.7% | 0.00% | -97.6% |
| Q2 2021 | $1,829,000 | +4843.2% | 36,000 | +1252.4% | 0.08% | +2733.3% |
| Q2 2018 | $37,000 | -64.4% | 2,662 | -59.4% | 0.00% | -66.7% |
| Q1 2018 | $104,000 | +160.0% | 6,562 | -19.0% | 0.01% | +800.0% |
| Q4 2017 | $40,000 | -77.0% | 8,098 | -74.7% | 0.00% | -83.3% |
| Q3 2017 | $174,000 | +411.8% | 31,976 | +657.5% | 0.01% | +500.0% |
| Q2 2017 | $34,000 | – | 4,221 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |